Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Lamotrigine). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Lamogin 25 is indicated for:
Pharmacology
Lamotrigine's exact mechanism of action has not been fully worked out, since it appears to act through several cellular pathways that together account for its usefulness across a range of conditions. Although chemically unrelated to phenytoin and carbamazepine, it produces similar effects: it inhibits voltage-sensitive sodium channels and stabilizes neuronal membranes, which in turn modulates the release of excitatory neurotransmitters from presynaptic nerve endings. Lamotrigine most likely works by binding selectively to sodium channels in their inactive state, blocking sodium currents and suppressing release of the excitatory amino acid glutamate. This same mechanism, which underlies its anticonvulsant activity, is thought to be responsible for its effect in managing bipolar disorder. Research has also found that lamotrigine binds to sodium channels in a manner similar to local anesthetics, which may explain the clinical benefit it shows in certain neuropathic pain conditions.
Lamotrigine also binds to a number of other receptors. In laboratory binding assays, it shows a weak inhibitory effect on the serotonin 5-HT3 receptor, and it binds weakly, with an IC50 above 100 µM, to adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, the kappa-opioid receptor (KOR), muscarinic acetylcholine receptors, and serotonin 5-HT2 receptors. Weak inhibitory effects have also been observed at sigma opioid receptors. An in vivo study found evidence that lamotrigine inhibits Cav2.3 (R-type) calcium currents, a mechanism that may further contribute to its anticonvulsant effects.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Table 1, the escalation regimen for lamotrigine in patients older than 12 years with epilepsy, is as follows. In weeks 1 and 2, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 25 mg every day; patients taking valproate take 25 mg every other day; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 50 mg per day. In weeks 3 and 4, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 50 mg per day; patients taking valproate take 25 mg every day; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 100 mg per day in two divided doses. From week 5 onward toward the maintenance dose, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate increase the dose by 50 mg per day every one to two weeks; patients taking valproate increase by 25 to 50 mg per day every one to two weeks; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate increase by 100 mg per day every one to two weeks. The usual maintenance dose for patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate is 225 to 375 mg per day in two divided doses. For patients taking valproate, the usual maintenance dose is 100 to 200 mg per day when valproate is the only other drug involved, or 100 to 400 mg per day in one or two divided doses when other drugs that induce glucuronidation are also being taken. For patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate, the usual maintenance dose is 300 to 500 mg per day in two divided doses.
Table 2 sets out the escalation regimen for lamotrigine in patients aged 2 to 12 years with epilepsy. In weeks 1 and 2, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 0.3 mg per kg per day in one or two divided doses; patients taking valproate take 0.15 mg per kg per day in one or two divided doses; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 0.6 mg per kg per day in two divided doses. In weeks 3 and 4, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 0.6 mg per kg per day in two divided doses; patients taking valproate take 0.3 mg per kg per day in one or two divided doses; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 1.2 mg per kg per day in two divided doses. From week 5 onward toward the maintenance dose, the dose should be increased every one to two weeks, calculated as 0.6 mg per kg per day for patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate, as 0.3 mg per kg per day for patients taking valproate, and as 1.2 mg per kg per day for patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate. The usual maintenance dose for patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate is 4.5 to 7.5 mg per kg per day, up to a maximum of 300 mg per day in two divided doses. For patients taking valproate, the usual maintenance dose is 1 to 3 mg per kg per day when valproate is the only other drug involved, or 1 to 5 mg per kg per day up to a maximum of 200 mg per day in one or two divided doses when other such drugs are also being taken. For patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate, the usual maintenance dose is 5 to 15 mg per kg per day, up to a maximum of 400 mg per day in two divided doses.
Table 3 is the initial weight based dosing guide for patients aged 2 to 12 years who are taking valproate, covering weeks 1 to 4. In weeks 1 and 2, a child weighing 6.7 kg to 14 kg takes 2 mg every other day; a child weighing 14.1 kg to 27 kg takes 2 mg every day; a child weighing 27.1 kg to 34 kg takes 4 mg every day; a child weighing 34.1 kg to 40 kg takes 5 mg every day. In weeks 3 and 4, a child weighing 6.7 kg to 14 kg takes 2 mg every day; a child weighing 14.1 kg to 27 kg takes 4 mg every day; a child weighing 27.1 kg to 34 kg takes 8 mg every day; a child weighing 34.1 kg to 40 kg takes 10 mg every day.
Table 4 gives the escalation regimen for lamotrigine in adults with bipolar disorder. In weeks 1 and 2, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 25 mg daily; patients taking valproate take 25 mg every other day; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 50 mg daily. In weeks 3 and 4, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 50 mg daily; patients taking valproate take 25 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 100 mg daily in divided doses. In week 5, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 100 mg daily; patients taking valproate take 50 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 200 mg daily in divided doses. In week 6, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 200 mg daily; patients taking valproate take 100 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 300 mg daily in divided doses. In week 7, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate continue on 200 mg daily; patients taking valproate continue on 100 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate may go up to 400 mg daily in divided doses.
Side Effects
Adults may experience dizziness, headache, double vision, unsteady movement, nausea, blurred vision, drowsiness, sore throat, and skin rash. Children may experience vomiting, diarrhea, infection, fever, abdominal pain, and tremor.
Cautions & Contraindications
Warnings & Precautions
Stop lamotrigine as soon as you notice any rash. Blood problems such as low neutrophils, low platelets or low blood cells of all types can happen with this medicine. Watch for signs of anaemia, infections that come on unexpectedly, or bleeding. Lamotrigine can also be linked to suicidal thoughts and behaviour, so keep an eye out for them. Aseptic meningitis is another possible effect, and you should watch for the signs of meningitis.
Pregnancy & Breastfeeding
Pregnancy Category C. Lamotrigine passes into human breast milk, and nursing infants may be at risk of serious adverse effects from exposure to the drug. Given this, the mother and her doctor should weigh how important the medicine is to her health against the risks to the baby, and decide together whether to stop breastfeeding or stop taking Lamotrigine.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Children and Lamotrigine
Pediatric Use
Epilepsy: Lamotrigine has not been shown to be safe or effective as an add-on treatment for partial onset seizures in very young children aged 1 to 24 months.
Bipolar Disorder: Lamotrigine has not been shown to be safe or effective for maintenance treatment of bipolar disorder in children and adolescents aged 10 to 17 years.
Overdose
Lamotrigine overdose has caused ataxia, nystagmus, seizures (including tonic-clonic seizures), a lowered level of consciousness, coma, and intraventricular conduction delay.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Lamotrigine out of the reach of children. Store it in a dry place, below 25°C, and protect it from light.
Drug Interactions
Common questions about Lamogin 25 25 mg
What is Lamogin 25 25 mg Tablet?
Lamogin 25 25 mg Tablet is a medicine that contains Lamotrigine. It is made by Incepta Pharmaceuticals Ltd. It belongs to the Primary anti-epileptic drugs group of medicines.
What is Lamogin 25 used for?
Lamogin 25 is used for: Epilepsy, Bipolar Disorder.
What are the side effects of Lamogin 25?
Adults may experience dizziness, headache, double vision, unsteady movement, nausea, blurred vision, drowsiness, sore throat, and skin rash. Children may experience vomiting, diarrhea, infection, fever, abdominal pain, and tremor.
Can I take Lamogin 25 during pregnancy or while breastfeeding?
Pregnancy Category C. Lamotrigine passes into human breast milk, and nursing infants may be at risk of serious adverse effects from exposure to the drug. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Lamogin 25?
Lamotrigine overdose has caused ataxia, nystagmus, seizures (including tonic-clonic seizures), a lowered level of consciousness, coma, and intraventricular conduction delay. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Lamogin 25?
Keep Lamotrigine out of the reach of children. Store it in a dry place, below 25°C, and protect it from light.
Can I take other medicines with Lamogin 25?
Some medicines can interact with Lamotrigine, for example: Carbamazepine, Atazanavir, Ritonavir, Primidone, Phenytoin, Phenobarbital. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Lamogin 25?
Lamogin 25 is a prescription (Rx) medicine. Take it as your doctor advises.